US › Healthcare

Revelation Biosciences Inc (REVB)

US · Healthcare · Biotechnology

$1.13+10.78%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-3.0M
Profit YoY
-46.7%
EPS
$-2.71
EPS estimate
$-1.15

EPS came in at -2.71 against a street estimate of -1.15 — a miss of 135.7%.

Key statistics

Market cap
$3.7M
Forward P/E
0.9
P/B
0.29
Book value
$3.32
EPS (TTM)
$-1.32
52-week high
$11.72
52-week low
$0.88
50-day MA
$1.04
200-day MA
$2.18
Beta
-0.12

Analyst view

Analysts rate Revelation Biosciences Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $19.25.

Shareholding

Insiders
4.79%
Institutions
12.79%

Largest institutional holders

FundStake
Armistice Capital, LLC8.27%
Sabby Management LLC2.54%
Geode Capital Management, LLC1.11%
Vanguard Fiduciary Trust Co0.34%
XTX Topco Ltd0.29%
UBS Group AG0.11%
Tower Research Capital LLC0.10%
Royal Bank of Canada0.02%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Revelation Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.